Errores en el proceso de cambio de sexo y etapa conservadora, transexual (página 2)

19. Dorff TB, Shazer RL, Nepomuceno EM, Tucker SJ. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. ClinGenitourin Cancer 2007; 5:344-6

20. Duwe KM, Shiau M, Budorick N, et al. Evaluation of the lower extremity veins in patients with suspected pulmonary embolism: A retrospective comparison of helical CT venography and sonography. Am J Roentgenol AJR 2000; 175: 1525-1531.

21. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC & Gooren LJ. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clinical Endocrinology 2003 58 562–571.

22. Elizabeth Ellent,, Marc R. Matrana. Metastatic Prostate Cancer 35 Years after Sex Reassignment Surgery. Clinical Genitourinary Cancer Month 2015

23. Fals-Stewart W, O'Farrell TJ, Lam WK. Behavioral couple therapy for gay and lesbian couples with alcohol use disorders. Journal of Substance Abuse Treatment. 2009; 37 :379–387.

24. Ferenci P., Herneth A., Stendil P.: Newer approaches to therapy of hepatic encephalopathy. Semin LiverDis16:329-1996

25. Frost DM, Meyer IH. Internalized homophobia and relationship quality among lesbians, gay men, and bisexuals. Journal of Counseling Psychology. 2009; 56 :97–109.

26. Furman RH. Are gonadal hormones (estrogens and androgens) of significance in the development of ischemic heart disease. Annals of the New York Academy of Sciences 1968 149 822–833

27. García-Cortés M, Andrade RJ, Lucena MI, Sánchez-Martínez H, Fernández MC, Ferrer T, y col. Hepatotoxicidad por flutamida: análisis retrospectivo de una serie. Rev Esp Enferm Dig 2001; 93: 424-427

28. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H & Stehouwer CD. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. Journal of Clinical Endocrinology and Metabolism 1998 83 550–55.

29. Gómez J L, Dupont A, Cusan L et al.: Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992; 92: 465-7 0 .

30. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 1992; 92: 465-470.

31. Gooren L El Tratamiento hormonal de la Paciente transexual adulta. Horm Res. 2005; 64 Suppl 2: 31-6.

32. Gooren L, Morgentaler A. la incidencia de cáncer de próstata en personas transexuales castrados macho a hembra tratadas con estrógenos. Andrologia. 2014 Dec; 46 (10): 1156-1160.

33. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.

34. Hendricks M, Testa R. A conceptual framework for clinical work with transgender and gender nonconforming clients: An adaptation of the Minority Stress Model. Professional Psychology: Research and Practice. 2012; 43 :460–467..

35. Hendricks ML, Testa RJ. A conceptual framework for clinical work with transgender and gender nonconforming clients: an adaptation of the Minority Stress Model. Prof Psychol Res Pr. 2012; 43 (5):460–467.

36. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, Deanfield JE, MacAllister RJ, Vallance P. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102:994-999, 2000.

37. Houk CP, Lee PA. The diagnosis and care of transsexual children and adolescents: a pediatric endocrinologists' perspective. J Pediatr Endocrinol Metab 2006; 19:103.

38. Iiyama K, Nagano M, Yo Y, Nagano N, Kamide K, Higaki J et al. Impaired endothelial function with essential hypertension assessed by ultrasonography. Hypertension 1996; 132: 779–782. |

39. Jefferson J.:Drug inducen hepatotoxicity. Intern Drug TherNewsletter40:25-April2005

40. Kinon B, Gilmore J, Liu H, Halbreich U. Prevalence hyperprolactinemia in schizophrenic patients treated with convencional medications or risperidone. Psychoneuroendocrinology 2003; 28: 55-68.

41. Krujver, F. P. M., Zhou, J. N., Pool, C. W., Hofman, M. A., Gooren, L. J. G. & Swaab, D. F. (2000). Male- to –female transsexuals have female neuron numbers in a limbic nucleus. The Journal of Clinical Endocrinology & Metabolism, 86 (5), 2034-2041

42. La Torre RA & Piper WE. La identidad de género y rol de género en la esquizofrenia. Journal of Abnormal Psychology 1979 88 68 ± 72.

43. Lazerow S., Abdi M., Lewis J.: Drug induced liver disease 2004- Curr Opin Gastroenterol 21:283-2005

44. Lombardi E. Substance use treatment experiences of transgender/transsexual men and women. Journal of LGBT Health Research. 2007.

45. Maddrey W.:Drug induced hepatotoxicity 2005. JClin Gastroenterol39:Suppl2, S83-2005

46. Marsh SA, Coombes JS. Exercise and the endothelial cell. Int J Cardiol. 2005; 99 (2):165-5.

47. Mereish EH, O'Cleirigh C, Bradford JB. Interrelationships between LGBT-based victimization, suicide, and substance use problems in a diverse sample of sexual and gender minorities. Psychol Health Med. 2014; 19 (1):1–13.

48. Metcalfe K, Lynch HT, Ghadirian P,Tung N, Olivotto I,Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;15:2328-2335.

49. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008; 122:2017-2022.

50. Metcalfe KA, Lubinski J, Ghadirian P. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26:1093-1097.

51. Metcalfe KA, Lynch HT, Ghadirian P.The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005; 96:222-226.

52. Miksad Rebeca A, Bubley G, Church P, et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA 2006; 296:2316-7.

53. Moller P, Borg A, Evans DG, Haites N, Reis MM,Vasen H, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumor characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002 ;101(6):555-559.

54. Molokwu N. Chidi. Detection of prostate cancer following gender reassignment. BJU International February 2008

55. Monstrey SJ, Ceulemans P, Hoebeke P. Sex Reassignment Surgery in the Female-to-Male Transsexual. Semin Plast Surg 2011; 25:229.

56. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467.

57. Mueller A, Dittrich R, Binder H, et al. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 2005; 153:107

58. Newcomb ME, Heinz AJ, Mustanki B. Examining risk and protective factors for alcohol use in lesbian, gay, bisexual and transgender youth: a longitudinal multilevel analysis. J Stud Alcohol Drugs. 2012; 73 (5):783–793.

59. Nuttbrock L, Bockting W, Rosenblum A. et al. Gender abuse and major depression among transgender women: a prospective study of vulnerability and resilience. Am J Public Health. 2013.

60. Nuttbrock L, Bockting W, Rosenblum A. et al. Gender abuse, depressive symptoms and HIV and sexually transmitted infections among male-to-female transgender persons: a three year prospective study. Am J Public Health. 2013; 103 (2):300–307.

61. Nuttbrock L, Bockting W, Rosenblum A. et al. Gender identity conflict/affirmation and major depression across the life course of transgender women. Int J Transgend. 2012; 13 (3):91–103.

62. Nuttbrock L, Hwahng S, Bockting W, Rosenblum A, Mason M, Macri M, Becker J. Psychiatric impact of gender-related abuse across the life course of male-to-female transgender persons. Journal of Sex Research. 2010; 47 :12–23.

63. Nuttbrock L, Hwahng S, Bockting W, Rosenblum A, Mason M, Macri M, Becker J. Psychiatric impact of gender-related abuse across the life course of male to female transgender persons. Journal of Sex Research. 2010

64. O"Grady J., Alexander G., Hayllar K.: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97:439-1989

65. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104:191-196, 2001.

66. Peterson DA, Kazerooni A, Wakefield TW et al. Computed tomographic venography is specific but not sensitive for diagnosis of acute lower extremity deep venous thrombosis in patients with suspected pulmonary embolus. J Vasc Surg 2001; 34: 798-804.

67. Pulerwitz T, Grahame-Clarke C, Rodriguez CJ, Miyake Y, Sciacca RR, Hirata K et al. Association of increased body mass index and impaired endothelial function among Hispanic women. Am J Cardiol 2006; 97(1): 68–70

68. Rush JWE, Denniss SG, Graham DA. Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol. 2005; 30 (4): 442-74.

69. Sedlak T1, Shufelt C, C Iribarren, Merz CN. Hormonas sexuales y el intervalo QT: un Womens Health review.J (Larchmt). 2012 septiembre; 21 (9): 933-41.

70. Thurston AV. Carcinoma of the prostate in a transsexual.Br.J.Urol.1994; 73:217.

71. Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013.

72. Van Haarst EP, Newling DW, Gooren LJ, Asscheman H, Prenger DM. Metastatic prostatic carcinoma in a male-to-female transsexual.Br J Urol1998; 81:776.

73. VinholtSchiodtF., LeeF:Fulminantliverdisease. Clin LiverDis7:331-2003

74. Zimmerman HJ: Acetaminophen Hepatotoxicity. Clinics in Liver Disease 1998; 2: 523-54

75. Zimmerman JH, Maddrey WC: Toxic and Drug-Induced Hepatitis. In Schiff L, Schiff ER (eds): Diseases of the Liver, ed. 5 Philadelphia, JI3 Lippincott, p 707-783,1993.

76. Zimmermann HJ. Drug-induced liver disease. Clinics in Liver Disease 2000; 4: 73-96.